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ABSTRACT
Background. The optimal iron therapy regimen in patients
with non-dialysis-dependent chronic kidney disease (CKD) is
unknown.
Methods. Ferinject® assessment in patients with Iron defici-
ency anaemia and Non-Dialysis-dependent Chronic Kidney
Disease (FIND-CKD) was a 56-week, open-label, multicentre,
prospective and randomized study of 626 patients with non-
dialysis-dependent CKD, anaemia and iron deficiency not re-
ceiving erythropoiesis-stimulating agents (ESAs). Patients were
randomized (1:1:2) to intravenous (IV) ferric carboxymaltose
(FCM), targeting a higher (400–600 μg/L) or lower (100–200 μg/L)
ferritin or oral iron therapy. The primary end point was time
to initiation of other anaemia management (ESA, other iron
therapy or blood transfusion) or haemoglobin (Hb) trigger of
two consecutive values <10 g/dL during Weeks 8–52.
Results. The primary end point occurred in 36 patients (23.5%),
49 patients (32.2%) and 98 patients (31.8%) in the high-ferritin
FCM, low-ferritin FCM and oral iron groups, respectively
[hazard ratio (HR): 0.65; 95% confidence interval (CI): 0.44–
0.95; P = 0.026 for high-ferritin FCM versus oral iron]. The in-
crease in Hb was greater with high-ferritin FCM versus oral iron
(P = 0.014) and a greater proportion of patients achieved an Hb
increase ≥1 g/dL with high-ferritin FCM versus oral iron (HR:
2.04; 95% CI: 1.52–2.72; P < 0.001). Rates of adverse events and
serious adverse events were similar in all groups.
Conclusions. Compared with oral iron, IV FCM targeting a
ferritin of 400–600 μg/L quickly reached and maintained Hb
level, and delayed and/or reduced the need for other anaemia
management including ESAs. Within the limitations of this
trial, no renal toxicity was observed, with no difference in car-
diovascular or infectious events.
ClinicalTrials.gov number. NCT00994318.
Keywords: anaemia, chronic kidney disease
INTRODUCTION
For the last 25 years, erythropoiesis-stimulating agents (ESAs)
and iron therapy have been the mainstay of anaemia management
in patients with chronic kidney disease (CKD), while blood trans-
fusions were only used when these therapies failed or when there
was an urgent clinical need. ESAs have been shown to be highly
effective in ameliorating anaemia in this setting [1]. However,
large randomized controlled trials in patients with CKD either
non-dialysed or on dialysis have shown that attempts to normal-
ize haemoglobin (Hb) with ESAs are associated with no benefit
for cardiovascular events or mortality, and an increased risk of
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Secondary analyses of these trials indicated that these risks may
be particularly prevalent in patients who are relatively unrespon-
sive to highdosages of ESAs [7–9]. As a consequence, the pre-
scription and dosage of ESAs have decreased, the number of
blood transfusions has increased and—since iron deficiency is
one of the main causes of hyporesponsiveness to ESAs—the use
of iron therapy in patients with CKD, has increased significantly
[10, 11]. However, in non-dialysis-dependent CKD patients with
anaemia and/or iron deficiency, intravenous (IV) iron therapy
remains far less widely utilized than in the dialysis population
[12].
In patients receiving haemodialysis, IV iron has been
shown to be significantly more effective than oral iron for re-
plenishing depleted iron stores, improving Hb levels and redu-
cing dosage requirements for ESAs [13–18]. However, in
patients with non-dialysis-dependent CKD, the evidence base
supporting optimal iron management is notably inadequate,
as demonstrated by both a recent meta-analysis of oral versus
IV iron in this patient population which included only six
studies [19] and a Cochrane review, which included 10 studies
[20] of relatively small size and short duration. Both these reports
[19, 20], as well as the Kidney Disease: Improving Global Out-
comes Clinical Practice Guideline for Anemia in Chronic Kidney
Disease [1], stress the need for more robust clinical trials with
longer follow-up in patients with non-dialysis-dependent CKD.
The Ferinject® assessment in patients with Iron deficiency
anaemia and Non-Dialysis-dependent Chronic Kidney Disease
(FIND-CKD) study assessed the 12-month efficacy and safety of
IV ferric carboxymaltose (FCM) compared with oral iron to
delay and/or reduce use of ESAs or other anaemia management
options in patients with non-dialysis-dependent CKD, anaemia
and iron deficiency not receiving an ESA. Iron therapy based on
different ferritin targets has not been previously studied, there-
fore, two different treatment strategies were assessed using a
dosing schema of IV FCM that was adjusted to achieve and
maintain ferritin target levels that were either higher (400–600
μg/L) or lower (100–200 μg/L).
MATERIALS AND METHODS
Trial design and oversight
FIND-CKD was a 56-week, open-label, multicentre, pro-
spective, randomized and three-arm study (ClinicalTrials.gov
NCT00994318). Patients were randomized at 193 nephrology
centres in 20 countries. The study design has been published
previously (Supplementary data, Figure S1) [21]. Additional
details of the methodology are provided in Appendix 2.
Recruitment
All inclusion and exclusion criteria are shown in Supple-
mentary data, Table S1. Adult (≥18 years) patients with non-
dialysis-dependent CKD were eligible if (i) at least one Hb
level was between 9 and 11 g/dL within 4 weeks of randomiza-
tion; (ii) any ferritin level was <100 or <200 μg/L with transfer-
rin saturation (TSAT) <20%, within 4 weeks of randomization;
(iii) estimated glomerular filtration rate (eGFR) was ≤60 mL/
min/1.73 m2 [Modification of Diet in Renal Disease-4 (MDRD-4)
equation [22]], the rate of eGFR loss was ≤12 mL/min/1.73 m²/
year and predicted eGFR at 12 months was ≥15 mL/min/1.73 m2;
and (iv) no ESA had been administered within 4 months of ran-
domization. Key exclusion criteria included anaemia due to
reasons other than iron deficiency, documented history of dis-
continuing oral iron products due to significant gastrointestinal
distress, known active infection, C-reactive protein >20 mg/L,
overt bleeding, active malignancy, chronic liver disease and con-
comitant New York Heart Association Class IV heart failure.
Randomization
Eligible patients were randomized via a central interactive
voice-response system in a 1:1:2 ratio (high-ferritin FCM: low-
ferritin FCM: oral iron), with randomization blocks distribu-
ted by country.
Study therapy and anaemia management
FCM dose (Ferinject®, Vifor International, St Gallen, Switz-
erland) in the high-ferritin and low-ferritin FCM groups was
adjusted to target a ferritin level of 400–600 and 100–200 μg/L,
respectively (Supplementary data, Figure S2). An initial single
dose was administered on Day 0: 1000 mg iron as FCM in the
high-ferritin FCM group (500 mg iron on Days 0 and 7 in pa-
tients weighing ≤66 kg) and 200 mg iron as FCM in the low-
ferritin FCM group if ferritin was <100 μg/L. DuringWeeks 4–48,
FCM was administered every 4 weeks in the high-ferritin FCM
group at a dose of 500 mg iron if ferritin was in the range 200
to <400 μg/L, and at a dose of 1000 mg iron if ferritin was
<200 μg/L, and in the low-ferritin FCM group at a dose of 200 mg
iron if ferritin was <100 μg/L. In both groups, dosing was with-
held if TSAT was ≥40%. FCM was provided as 10 mL vials con-
taining 500 mg iron per vial or 2 mL vials containing 100 mg
iron per vial. Oral iron therapy consisted of commercially
available ferrous sulphate at a dose of 100 mg iron twice daily
to Week 52. Ferrous sulphate was supplied by Vifor Pharma
(Plastufer® 100 mg capsules, Haupt Pharma Münster GmbH
and Valeant Pharmaceuticals Germany GmbH). Returned unused
oral iron capsules at each visit were counted to assess compliance.
During the first 8 weeks after randomization, patients were
not to receive ESAs, blood transfusion or any anaemia therapy
other than study drug unless there was an absolute requirement
(e.g. severe or serious adverse reaction to study drug or otherwise
unable to continue study drug, or rapid Hb drop requiring an
ESA or transfusion, at the investigator’s discretion). Subsequent-
ly, ESAs and other therapies were permitted according to local
practice if the Hb was <10 g/dL. Use of ESAs was not permitted
if the Hb level was ≥10 g/dL. Alternative iron therapy in patients
with Hb >10 g/dL could be used but only when a patient was
not able to comply with or tolerate the randomized treatment.
Primary and secondary end points
The primary end point of the study was time to initiation
of other anaemia management, specified as ESAs, blood trans-
fusion, use of an alternative iron therapy (i.e. product, dosing
schedule or total dose different from study drug) or occurrence
of an Hb trigger (two consecutive Hb values <10 g/dL on or
after Week 8, without an increase of ≥0.5 g/dL between the
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assessments). Secondary end points included percentage of pa-
tients requiring a blood transfusion; percentage of patients
with an increase of Hb ≥1 g/dL; change in haematologic and
iron indices from baseline to end of study; change in eGFR
(MDRD-4 [22]) from baseline to end of study; percentage of
patients requiring dialysis; percentage of patients discontinu-
ing study drug due to intolerance; and change in health-
related quality of life using the SF-36.
Statistical analysis
All patients who received at least one dose of randomized
treatment (or according to the protocol were not treated due
to ferritin level) and who attended at least one post-baseline
visit were included in the intention-to-treat (ITT) population.
All patients who received at least one dose of randomized
treatment were included in the safety population.
The primary end point, time to initiation of other anaemia
management or Hb trigger, was analyzed in the ITT popula-
tion based on Kaplan–Meier survival analyses using the log-
rank test to compare treatment arms. Patients who did not
meet the end point were censored at the time of study comple-
tion or discontinuation. The hazard ratios (HRs) and asso-
ciated 95% confidence intervals (CIs) from Cox proportional
hazards modelling were also calculated as a supportive ana-
lysis. Three primary comparisons were made using a hierarch-
ical step-down procedure to preserve the overall α level of 0.05,
in the following order: (i) high-ferritin FCM versus oral iron, (ii)
high-ferritin FCM versus low-ferritin FCM and (iii) low-ferritin
FCM versus oral iron.
All other analyses were exploratory. For continuous second-
ary end points, either analysis of variance or analysis of co-
variance models were used, implementing repeated measures
procedure where appropriate, and including treatment group,
age, baseline Hb and/or baseline ferritin as covariates. For
non-continuous end points (e.g. blood transfusion, require-
ment for dialysis), survival curves and logistic regressions were
performed and odds ratios were used to compare treatment
groups. The statistical analysis plan specified that analyses of
haematological values and iron parameters (e.g. Hb, ferritin,
TSAT), adverse events and serious adverse events were only
for assessments up to the point at which another anaemia
therapy was initiated and/or the randomized study medication
was discontinued. No adjustment was made for testing mul-
tiple secondary outcomes.
All statistical analyses were performed using SAS Version
9.3 (SAS Institute Inc. SAS/STAT, Cary, NC).
RESULTS
Study population
From December 2009 to January 2012, 626 patients from
193 sites in 20 countries were randomized (Figure 1). The
study was completed by 519 patients (82.9%). The most fre-
quent reasons for discontinuation were patient withdrawal or
death (12.9% in the FCM treatment arms versus 21.1% in the
oral iron arm). The groups were well balanced with respect to
demographic and baseline characteristics, with no clinically
significant between-group differences (Table 1).
Treatment
The mean (SD) cumulative dose of FCM before initiation
of any other anaemia therapy was 2685 (978) mg iron in
the high-ferritin group and 1040 (618) mg iron in the low-
ferritin group (with corresponding median values of 2500 and
1000 mg iron, respectively). The mean (SD) number of FCM
injections required to reach and maintain the target ferritin
was 4.0 (1.7) (range 1–10) and 4.8 (3.1) (range 1–14) in the
high-ferritin and low-ferritin groups, respectively. In the high-
ferritin group, patients received either 1000 or 500 mg iron to
maintain a ferritin of 400–600 μg/L. In the low-ferritin group,
the majority of patients received 200 mg iron to maintain a
ferritin of 100–200 μg/L. The proportion of patients requiring
an injection of FCM decreased progressively over time (Sup-
plementary data, Figure S3). Non-adherence (<80% of pre-
scribed study drug dose) was 16.4% in the oral iron treatment
group and ≤2% in each of the FCM treatment groups.
Primary end point
Time to initiation of other anaemia management or occur-
rence of anHb trigger (two consecutive Hb values <10 g/dL dur-
ing Weeks 8–52) as assessed by Kaplan–Meier survival analysis
was significantly different between the high-ferritin FCM group
versus oral iron (HR: 0.65; 95% CI: 0.44–0.95; P = 0.026). The
primary end point occurred in 36 patients (23.5%), 49 patients
(32.2%) and 98 patients (31.8%) in the high-ferritin FCM, low-
ferritin FCM and oral iron groups, respectively. Assessing the
effectiveness of high-ferritin FCM versus oral iron, the number
needed to treat to prevent either the initiation of other anaemia
management or occurrence of an Hb trigger was 12.
The next comparison in the pre-defined hierarchical step-
down procedure demonstrated no significant difference between
the high-ferritin and low-ferritin FCM treatment arms (HR:
0.68; 95% CI: 0.45–1.058; P = 0.082). In a pre-specified sensitiv-
ity analysis, the primary end point was assessed based on locally
measured Hb levels, which were used by investigators to make
immediate anaemia management decisions. This additional
analysis confirmed the primary analysis result that the high-
ferritin FCM group was less likely than the oral iron group to
require other anaemia treatment or reach the Hb trigger (HR:
0.62; 95% CI: 0.43–0.88; P = 0.008) (Table 2).
Overall, other anaemia management (118 events) compris-
ing ESA therapy (58 events), blood transfusion (28 events),
other iron therapy (25 events) or a combination of therapies (7
events) was the most commonly reported first event contribut-
ing to the primary end point, followed by Hb trigger (65
events). While ESA alone was the most common first alterna-
tive therapy used across all three treatment groups (10.5, 11.8
and 7.8% of patients in the high-ferritin, low-ferritin and oral
iron groups, respectively) the oral iron group tended to receive
other iron therapy as the first alternative anaemia therapy
more often (6.5%) compared with either the high- or low-
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Secondary end points
The requirement for blood transfusion was low during the
course of the study and similar between treatment groups
(Table 2).
All three groups showed an increase in Hb of 0.9–1.4 g/dL
[least squares (LS) mean] from baseline to Month 12 without
ESA (Table 2). The increase in LS mean Hb level in the high-
ferritin FCM group versus the oral iron group was significant-
ly greater from baseline to Month 12 (P = 0.014) (Table 2),
and to all other time points (all P < 0.05, Figure 2B). In add-
ition, the haematological response was faster (Figure 2B). The
proportion of patients achieving an increase in Hb level ≥1 g/
dL was 56.9, 34.2 and 32.1% in the high-ferritin FCM, low-
ferritin FCM and oral iron groups, respectively. Patients in
the high-ferritin FCM group were more likely to achieve an
increase in Hb ≥1 g/dL compared with patients in either the
low-ferritin FCM group (HR: 2.11; 95% CI: 1.49–2.98; P <
0.001) or oral iron group (HR: 2.04; 95% CI: 1.52–2.72; P <
0.001). The LS mean (SE) ferritin level at Month 12 was 503
(11) μg/L in the high-ferritin FCM group, the mid-point of the
target range (400–600 μg/L) (Table 2, Figure 2C). LS mean (SE)
TSAT level at Month 12 was similar in the high-ferritin FCM
group and the oral iron group, with the lowest value observed in
the low-ferritin FCM group (Table 2 and Figure 2D). eGFR was
similar in all three treatment groups at baseline and at Month
12, with no marked change in renal function in any group
during the study (Table 2). In total, 16 patients (2.6%) pro-
gressed to dialysis by Month 12, with no difference between
groups.
Overall patient-reported quality of life outcomes, as mea-
sured by SF-36, did not show a statistically significant differ-
ence by treatment assignment.
Safety
A similar proportion of patients in each group had at least
one adverse event during the study prior to the initiation of
other anaemia management or occurrence of Hb trigger or
discontinuation from study (high-ferritin FCM 81.8%, low-
ferritin FCM 86.0% and oral iron 81.7%). The most common
adverse events were peripheral oedema, hypertension, urinary
tract infection and back pain in the FCM treatment groups
(Table 3). In the oral iron group, diarrhoea, constipation, hy-
pertension and peripheral oedema were the most commonly
reported adverse events. Of the adverse events reported, 14.3,
15.3 and 28.5% were considered treatment related in the high-
ferritin FCM, low-ferritin FCM and oral iron groups, respect-
ively. Two patients in the low-ferritin FCM group experienced
a drug hypersensitivity reaction, one of which was graded mild
and the other graded moderate in severity by the investigator.
Both led to withdrawal of study drug but neither case required
treatment nor hospitalization, and there were no adverse se-
quelae. The mean serum phosphate level decreased by 0.18
F IGURE 1 : Enrolment and outcomes. The ITT population comprised all patients who received at least one dose of randomized treatment, or
according to the protocol were not treated due to ferritin level, and attended at least one post-baseline visit. The safety population included all
patients who received at least one dose of randomized treatment, and included 154 patients in the high-ferritin FCM group, 150 patients in the
low-ferritin FCM group and 312 patients in the oral iron group. Two patients randomized to the low-ferritin FCM group met the eligibility re-
quirements at screening but did not require FCM during the study according to the protocol-specified criteria for ferritin. These two patients
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mmol/L at Week 4 from a baseline value of 1.22 (0.2) mmol/L
in the high-ferritin FCM group, but returned to baseline by
Month 12 (Supplementary data, Figure S4). Therewere no cases
of hypophosphataemia reported as adverse events. Serious
adverse events were reported in 25.3, 24.0 and 18.9% of pa-
tients in the high-ferritin FCM, low-ferritin FCM and oral iron
groups, respectively. None of the serious adverse events in the
FCM treatment groups and one (0.3%) in the oral iron group
were considered treatment related. Benign or malignant neo-
plasms were reported in 12 patients (7.8%) in the high-ferritin
FCM arm, five patients (3.3%) in the low-ferritin FCM arm
and eight patients (2.6%) in the oral iron group. No type of
neoplasm occurred in more than one patient in any group
except for basal cell carcinoma (three in the high-ferritin FCM
arm) and multiple myeloma (two in the oral iron arm). The
most commonly reported serious adverse events by organ class
were cardiac disorders and infections and were similar between
treatment groups (Table 3).
Study drug was discontinued due to intolerance in one
patient (0.7%) in the high-ferritin FCM group, two patients
(1.3%) in the low-ferritin FCM group and 23 patients in the
oral iron group (7.5%) (HR: 0.08; 95% CI: 0.01–0.62; P = 0.002
for high-ferritin FCM versus oral iron). Of the 23 patients who
discontinued oral iron therapy, 15 stopped treatment before
Week 8 (65.2%). Adverse events leading to discontinuation
from study occurred in five (3.2%) patients in the high-ferritin
FCM group, seven (4.7%) in the low-ferritin FCM group and
42 (13.5%) in the oral iron group. Gastrointestinal disorders
did not lead to study drug discontinuation in any patients
receiving FCM but contributed to intolerance in 23 patients
receiving oral iron (7.5%) who discontinued treatment.
During the 56-week study period, 25 patients died (4.1%).
None of the deaths was assessed by the investigator as related
to study drug. Twelve deaths occurred prior to initiation of
other anaemia treatment, occurrence of the Hb trigger or dis-
continuation of study drug and 13 deaths occurred
Table 1. Baseline demographics and characteristics of patients in the ITT population according to study treatment arma
High-ferritin FCM (n = 153) Low-ferritin FCM (n = 152) Oral iron (n = 308)
Age (years) 69.5 (12.6) 68.2 (13.3) 69.3 (13.4)
Age >75 years, n (%) 54 (35.3) 54 (35.3) 121 (39.3)
Female gender, n (%) 91 (59.5) 98 (64.5) 192 (62.3)
Race, n (%)
White 149 (97.4) 144 (94.7) 291 (94.5)
Black 2 (1.3) 5 (3.3) 7 (2.3)
Asian 2 (1.3) 3 (2.0) 9 (2.9)
Body mass index (kg/m2) 29.7 (6.6) 29.9 (6.0) 29.1 (5.9)
History of diabetes, n (%) 88 (57.5) 97 (63.8) 195 (63.3)
eGFR (mL/min/1.73 m2)b
Mean (SD) 32.8 (11.7) 31.5 (10.7) 32.3 (11.6)
eGFR ≥60, n (%) 2 (1.3) 1 (0.7) 3 (1.0)
eGFR 30 to <60, n (%) 86 (56.2) 79 (52.0) 167 (54.2)
eGFR 15 to <30, n (%) 62 (40.5) 69 (45.4) 128 (41.6)
eGFR <15, n (%) 3 (2.0) 3 (2.0) 10 (3.2)
Endogenous erythropoietin (mIU/mL)c
Mean (SD) 28.2 (30.0) 27.1 (25.0) 31.4 (91.5)
Median (range) 20.3 (3.6, 272.0) 20.7 (4.9, 187.0) 19.1 (3.8, 1531.0)
Hb (g/dL)c
Mean (SD) 10.3 (0.7) 10.5 (0.8) 10.4 (0.7)
<10, n (%) 43 (28.1) 32 (21.1) 73 (23.7)
≥10 106 (69.3) 112 (73.7) 229 (74.4)
Ferritin (μg/L)c
Mean (SD) 57.7 (48.1) 56.4 (49.2) 57.3 (42.4)
<100, n (%) 123 (80.4) 124 (81.6) 251 (81.5)
≥100, n (%) 23 (15.0) 22 (14.5) 41 (13.3)
TSAT (%)d
Mean (SD) 16.2 (16.7) 16.1 (8.3) 15.5 (7.6)
<20, n (%) 112 (73.2) 114 (75.0) 215 (69.8)
≥20, n (%) 32 (20.9) 34 (22.4) 78 (25.3)
C-reactive protein (mg/L)d
Mean (SD) 6.7 (11.3) 6.2 (9.1) 5.2 (6.1)
Median (range) 3.5 (0.0, 99.7) 4.0 (0.0, 94.0) 3.5 (0.0, 59.1)
Hepcidin (nmol/L)c,e
Mean (SD) 1.43 (1.24) 2.60 (2.23) 2.30 (2.01)
Median (range) 1.15 (0.02, 3.54) 2.11 (0.12, 9.99) 1.87 (0.05, 7.63)
eGFR, estimated glomerular filtration rate; FCM, ferric carboxymaltose; Hb, haemoglobin; TSAT, transferrin saturation.
aContinuous variables are shown as mean (SD) unless otherwise stated.
bEstimated by MDRD-4 equation [22] at local laboratory.
cMeasured at central laboratory.
dMeasured at local laboratory.
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subsequently. There were seven deaths (4.5%) in the high-fer-
ritin FCM arm, three (2.0%) in the low-ferritin FCM arm and
15 (4.8%) in the oral iron arm. The average age of the patients
who died was 74.6 years and the most frequently reported
causes of death were cardiovascular events or respiratory
infections.
Table 2. Primary end point and selected secondary end points (ITT population)a
High-ferritin FCM (n = 153) Low-ferritin FCM (n = 152) Oral iron (n = 308)
Primary end point
Time to initiation of other anaemia management or Hb trigger (central monitoring)b,e
n (%) 36 (23.5) 49 (32.2) 98 (31.8)
HR (95% CI)c Reference 0.68 (0.45, 1.05) 0.65 (0.44, 0.95)
P-value (log-rank) Reference 0.082 0.026
Events contributing to primary end point
Hb triggerb 10 (6.5) 19 (12.5) 36 (11.7)
ESA only 16 (10.5) 18 (11.8) 24 (7.8)
Other iron therapy only 0 5 (3.3) 20 (6.5)
ESA and iron therapy 0 2 (1.3) 2 (0.6)
Transfusion 9 (5.9) 5 (3.3) 14 (4.5)
ESA and transfusion 1 (0.7) 0 2 (0.6)
Primary end point
Time to initiation of other anaemia management or Hb trigger (local monitoring)b,d,e
n (%) 40 (26.1) 55 (36.2) 115 (37.3)
HR (95% CI)c Reference 0.68 (0.45, 1.03) 0.62 (0.43, 0.88)
P-value (log-rank) Reference 0.064 0.008
Secondary end points
Blood transfusion
n (%) 11 (7.2) 11 (7.2) 26 (8.4)
Odds ratio (95% CI) 0.89 (0.42, 1.88) 0.97 (0.46, 2.04) Reference
P-value 0.77 0.94 Reference
Time to Hb increase ≥1 g/dLe,f,g
n (%) 87 (56.9) 52 (34.2) 99 (32.1)
HR (95% CI) Reference 2.11 (1.49, 2.98) 2.04 (1.52, 2.72)
P-value (log-rank) Reference <0.001 <0.001
Hb, LS mean (SE) (g/dL)f,h
Baseline 10.1 (0.1) 10.2 (0.1) 10.2 (0.1)
Month 12 12.0 (0.1) 11.5 (1.1) 11.5 (0.1)
Change from baseline 1.4 (0.1) 0.9 (0.1) 1.0 (0.1)
P-value (change from baseline to Month 12 versus oral ironi) 0.014 0.26 Reference
Ferritin, LS mean (SE) (μg/L)f,h
Baseline 54 (9) 48 (9) 53 (6)
Month 12 503 (11) 125 (11) 184 (8)
Change from baseline 451 (10) 81 (11) 137 (8)
P-value (change from baseline to Month 12 versus oral ironi) <0.001 <0.001 Reference
TSAT, LS mean (SE) (%)f,h
Baseline 16.2 (1.0) 16.1 (1.0) 15.5 (0.7)
Month 12 31.2 (1.3) 24.2 (1.3) 28.6 (1.0)
Change from baseline 15.8 (1.3) 8.5 (1.3) 13.8 (1.0)
P-value (change from baseline to Month 12 versus oral ironi) 0.20 0.001 Reference
eGFR, LS mean (SE) (mL/min/1.73 m2)j
Baseline 32.1 (1.1) 31.8 (1.1) 33.2 (0.8)
Month 12 35.3 (1.4) 31.1 (1.4) 33.7 (1.0)
Change from baseline 0.4 (0.8) −1.6 (0.8) −1.1 (0.6)
P-value (change from baseline to Month 12 versus oral ironi) 0.14 0.64 Reference
Requirement for dialysis
n % 5 (3.3) 1 (0.7) 10 (3.2)
Odds ratio (95% CI) 1.01 (0.34, 3.00) 0.20 (0.03, 1.56) Reference
P-value 0.99 0.12 Reference
eGFR, estimated glomerular filtration rate; FCM, ferric carboxymaltose; Hb, haemoglobin; LS, least squares; TSAT, transferrin saturation.
aContinuous variables are shown as mean (SD).
bTime to initiation of other anaemia management such as an ESA or transfusion, or an Hb trigger (two consecutive Hb values <10 g/dL on or after Week 8, without an increase of ≥0.5 g/dL




fMeasured at local laboratory.
gPrior to first initiation of other anaemia management.
hMeasurements were included up to the point at which other anaemia therapy was initiated and/or the randomized study medication was discontinued.
iAnalysis of covariance analysis based on LS mean values.
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DISCUSSION
This randomized trial met its primary end point and showed
that in patients with non-dialysis-dependent CKD, anaemia
and iron deficiency not receiving an ESA, IV FCM targeting a
ferritin of 400–600 μg/L is more effective than oral iron in de-
laying and/or reducing the requirement for an ESA, other anae-
mia management or the occurrence of two consecutive Hb
levels <10 g/dL. There was no significant difference between
the FCM treatment arms targeting a higher versus lower fer-
ritin range. There was also no apparent difference between the
low-ferritin FCM and oral iron groups, although no statistical
analysis was performed to compare these two treatment arms,
as per the hierarchical step-down procedure, which was pre-
defined in the study protocol.
In the setting of this controlled trial, the use of blood trans-
fusion was low and similar in all three treatment groups. Each
group showed an increase in mean values for ferritin, TSAT
and Hb from baseline to Month 12. Mean ferritin levels within
the pre-specified target ranges were achieved and maintained
in both of the FCM treatment arms. The mean increase in Hb
prior to the initiation of other anaemia therapy in all three
treatment groups was 0.9–1.4 g/dL. However, patients in the
high-ferritin FCM group had a faster haematological response
and were more likely to have an increase in Hb ≥1 g/dL.
Early iron dosing of 500–1000 mg in the high-ferritin FCM
group successfully achieved and maintained the ferritin target with
relatively few subsequent injections. No more than 25% of patients
in the high-ferritin FCM group required an injection at any study
visit after Month 4, whereas patients in the oral iron group were
required to take one capsule twice daily for 12 months.
Overall, 21.1% of patients in the oral iron group discontin-
ued the study compared with 14.2 and 11.7% in the high-fer-
ritin and low-ferritin FCM arms, respectively. In addition, 23
patients in the oral iron group discontinued study drug due to
intolerance (7.5%), and of these patients 65% discontinued
within the first 8 weeks of the study.
Although previous studies in laboratory experiments,
animal models and patients have raised concerns about pos-
sible nephrotoxicity of IV iron agents [23], no clinically rele-
vant deterioration in renal function was observed in any of the
treatment groups during this 12-month trial.
Potential other concerns that have been associated with IV
iron therapy include hypersensitivity reactions, hypophospha-
taemia, oxidative stress (which may increase the risk of cardio-
vascular events) and exacerbation of infection. In the current
study, two patients had a hypersensitivity reaction to IV iron
therapy. The reactions were not severe and resolved spontan-
eously with no sequelae. There were no clinically significant
hypophosphataemic episodes, although there was an early and
transient decrease in the mean serum phosphate level in the
high-ferritin FCM group. Markers of oxidative stress were not
assessed in this study, but the incidence of cardiovascular
events, deaths and infections was similar between treatment
groups. We observed a numerically higher percentage of
F IGURE 2 : (A) Time to initiation of other anaemia management or Hb trigger (Kaplan–Meier estimates) and LS mean locally measured
observed values over time for (B) Hb (C) ferritin and (D) TSAT according to treatment group (ITT population). Measurements of Hb, ferritin
and TSAT were included up to the point at which other anaemia therapy was initiated (with or without cessation of randomized study drug)
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benign and malignant neoplasms in the high-ferritin FCM
arm as compared with the two other arms. However, the abso-
lute numbers were small and there was no increase in any spe-
cific type of neoplasm. In addition, this trial was not powered
to assess a safety end point, therefore, we cannot make any
firm conclusions about the long-term risk : benefit ratio. Fur-
thermore, this study does provide safety data over a 56-week
period, which is considerably longer than previous trials of IV
iron in patients with CKD that have frequently only followed
patients for up to 8 weeks [24–28].
The study has several limitations. There was no placebo
arm in the study, thus precluding a comparison of efficacy and
safety between the interventions and no treatment. Moreover,
an open-label study design was used so that both the physi-
cians and patients were aware of the treatment allocation.
Avoiding this would have required a double-blind, double-
dummy design and at the time the study was being designed it
was not considered ethically appropriate to administer placebo
IV iron injections, potentially every 4 weeks for a year. The
generalizability of improvements in Hb and iron status in the
oral iron group to the wider non-dialysis-dependent CKD
population may be limited for several reasons. The patients
were predominantly white, had a low-inflammatory status (fa-
cilitating the absorption and utilization of oral iron) and
showed a degree of tolerance and compliance with oral iron
treatment that is unlikely to be matched in everyday clinical
practice. In addition, patients were excluded who had a history
of intolerance to oral iron prior to study entry. A further signi-
ficant limitation is that we did not include more patient-
centred outcome measurements.
In conclusion, patients with non-dialysis-dependent CKD,
anaemia and iron deficiency may benefit from IV iron treat-
ment targeting a higher ferritin level. Both IV and oral iron
therapy were effective in increasing Hb, ferritin and TSAT









Any adverse event, n (%) 126 (81.8) 129 (86.0) 255 (83.9) 255 (81.7)
Gastrointestinal disorders 32 (20.8) 38 (25.3) 70 (23.0) 128 (41.0)
Diarrhoea 15 (9.7) 11 (7.3) 26 (8.6) 45 (14.4)
Constipation 2 (1.3) 5 (3.3) 7 (2.3) 37 (11.9)
Nausea 9 (5.8) 7 (4.7) 16 (5.3) 15 (4.8)
Dyspepsia 2 (1.3) 3 (2.0) 5 (1.6) 17 (5.4)
Infections 51 (33.1) 51 (34.0) 102 (33.6) 95 (30.4)
Urinary tract infection 18 (11.7) 10 (6.7) 28 (9.2) 17 (5.4)
Nasopharyngitis 13 (8.4) 10 (6.7) 23 (7.6) 16 (5.1)
Influenza 4 (2.6) 8 (5.3) 12 (3.9) 7 (2.2)
General disorders and administrative site conditions 36 (23.4) 35 (23.3) 71 (23.4) 67 (21.5)
Peripheral oedema 21 (13.6) 21 (14.0) 42 (13.8) 29 (9.3)
Musculoskeletal and connective tissue disorders 35 (22.7) 42 (28.0) 77 (25.3) 56 (17.9)
Back pain 15 (9.7) 12 (8.0) 27 (8.9) 11 (3.5)
Arthralgia 10 (6.5) 7 (4.7) 17 (5.6) 15 (4.8)
Pain in extremity 2 (1.3) 8 (5.3) 10 (3.3) 15 (4.8)
Vascular disorders 33 (21.4) 26 (17.3) 59 (19.4) 52 (16.7)
Hypertension 21 (13.6) 14 (9.3) 35 (11.5) 32 (10.3)
Hypotension 8 (5.2) 4 (2.7) 12 (3.9) 5 (1.6)
Respiratory, thoracic and mediastinal disorders 19 (12.3) 27 (18.0) 46 (15.1) 41 (13.1)
Dyspnoea 7 (4.5) 11 (7.3) 18 (5.9) 11 (3.5)
Nervous system disorders 25 (16.2) 28 (18.7) 53 (17.4) 33 (10.6)
Dizziness 9 (5.8) 8 (5.3) 17 (5.6) 7 (2.2)
Headache 6 (3.9) 10 (6.7) 16 (5.3) 7 (2.2)
Blood and lymphatic system disorders 8 (5.2) 11 (7.3) 19 (6.3) 13 (4.2)
Anaemia 7 (4.5) 8 (5.3) 15 (4.9) 10 (3.2)
Serious adverse event, n (%) 39 (25.3) 36 (24.0) 75 (24.7) 59 (18.9)
Cardiac disorders 10 (6.5) 7 (4.7) 17 (5.6) 14 (4.5)
Acute myocardial infarction 2 (1.3) 0 (0) 2 (0.7) 4 (1.3)
Cardiac failure 1 (0.6) 0 (0) 1 (0.3) 3 (1.0)
Infections 6 (3.9) 5 (3.3) 11 (3.6) 12 (3.8)
Pneumonia 0 (0) 1 (0.7) 1 (0.3) 4 (1.3)
Injury, poisoning and procedural complications 4 (2.6) 3 (2.0) 7 (2.3) 8 (2.6)
Neoplasms (benign and malignant) 8 (5.2) 3 (2.0) 11 (3.6) 2 (0.6)
Gastrointestinal disorders 3 (1.9) 6 (4.0) 9 (3.0) 2 (0.6)
Nervous system disorders 2 (1.3) 1 (0.7) 3 (1.0) 6 (1.9)
Respiratory, thoracic and mediastinal disorders 1 (0.6) 2 (1.3) 3 (1.0) 6 (1.9)
Chronic obstructive pulmonary disease 0 2 (1.3) 2 (0.7) 2 (0.6)
Vascular disease 2 (1.3) 3 (2.0) 5 (1.6) 4 (1.3)
FCM, ferric carboxymaltose.
Listed are the most common adverse events according to body system (occurring in ≥10% of patients in any group) and as individual types of events (occurring in ≥5% of patients in any
group). Serious adverse events are listed if they occurred in ≥1% of patients in any study group. Adverse events and serious adverse events are reported up to the point at which another
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levels in this setting; however, FCM therapy with a higher fer-
ritin target was shown to be superior to oral iron in delaying
and/or reducing the requirement for other anaemia manage-
ment or occurrence of an Hb trigger during the 12-month
study, as well as producing a faster haematological response
with a greater proportion of patients achieving an Hb increase
of ≥1 g/dL. These results were achieved with relatively few
FCM injections and despite selecting patients for inclusion in
the study who might be expected to do well on oral iron
therapy. High-ferritin FCM was well tolerated, with fewer
treatment-related adverse events and study discontinuations
versus oral iron and within the limitations of this trial, no
renal toxicity and no increases in cardiovascular or infectious
events were observed. These findings support current guide-
lines [1], which recommend a trial of iron therapy if an in-
crease in Hb without ESA therapy is desired in patients with
CKD, anaemia and iron deficiency. Furthermore, based on the
findings in this study, targeting a higher ferritin level with IV
FCM may contribute to improved anaemia management.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
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ABSTRACT
Background. Minimal-change nephrotic syndrome (MCNS)
is a common cause of steroid sensitive nephrotic syndrome
(NS) with frequent relapse. Although steroids and calcineurin
inhibitors (CNIs) are the cornerstone treatments, the use of ri-
tuximab (RTX), a monoclonal antibody targeting B cells, is an
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